Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PRN with or without laser versus laser for macular edema due to branch retinal vein occlusion
2011-002859-34Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in branch retinal vein occlusion (BRVO) and macular edema (3 arms), sponsored by Novartis. Started Nov 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on 2011-002859-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002859-34.